Ifergan I - Search Results

1

Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.

Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Ifergan I, et al. J Biol Chem. 2004 Jun 11;279(24):25527-34. doi: 10.1074/jbc.M401725200. Epub 2004 Mar 26. J Biol Chem. 2004. PMID: 15047700 Free article.

2

Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines.

Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Rothem L, et al. Among authors: ifergan i. Biochem J. 2002 Nov 1;367(Pt 3):741-50. doi: 10.1042/BJ20020801. Biochem J. 2002. PMID: 12139489 Free PMC article.

3

Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells.

Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, Dijkmans BA, Peters GJ, Jansen G. Assaraf YG, et al. Among authors: ifergan i. J Biol Chem. 2003 Feb 28;278(9):6680-6. doi: 10.1074/jbc.M209186200. Epub 2002 Dec 16. J Biol Chem. 2003. PMID: 12486126 Free article.

4

Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.

Ifergan I, Meller I, Issakov J, Assaraf YG. Ifergan I, et al. Cancer. 2003 Nov 1;98(9):1958-66. doi: 10.1002/cncr.11741. Cancer. 2003. PMID: 14584080 Free article.

5

Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation.

Ifergan I, Jansen G, Assaraf YG. Ifergan I, et al. Mol Pharmacol. 2005 Apr;67(4):1349-59. doi: 10.1124/mol.104.008250. Epub 2005 Jan 18. Mol Pharmacol. 2005. PMID: 15657365

6

ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.

Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG. Shafran A, et al. Among authors: ifergan i. Cancer Res. 2005 Sep 15;65(18):8414-22. doi: 10.1158/0008-5472.CAN-04-4547. Cancer Res. 2005. PMID: 16166320 Free article.

7

Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.

Ifergan I, Scheffer GL, Assaraf YG. Ifergan I, et al. Cancer Res. 2005 Dec 1;65(23):10952-8. doi: 10.1158/0008-5472.CAN-05-2021. Cancer Res. 2005. PMID: 16322243

8

Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss.

Kaufman Y, Ifergan I, Rothem L, Jansen G, Assaraf YG. Kaufman Y, et al. Among authors: ifergan i. Blood. 2006 Apr 15;107(8):3288-94. doi: 10.1182/blood-2005-10-4048. Epub 2005 Dec 20. Blood. 2006. PMID: 16368880 Free article.

9

Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.

Bram E, Ifergan I, Shafran A, Berman B, Jansen G, Assaraf YG. Bram E, et al. Among authors: ifergan i. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. doi: 10.1007/s00280-006-0230-9. Epub 2006 Apr 13. Cancer Chemother Pharmacol. 2006. PMID: 16612649

10

C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG. Bram EE, et al. Among authors: ifergan i. Biochem Pharmacol. 2007 Jun 30;74(1):41-53. doi: 10.1016/j.bcp.2007.03.028. Epub 2007 Apr 1. Biochem Pharmacol. 2007. PMID: 17481587

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters